Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal to Sclerostin - BSA and Azide free (Detector)
- Suitable for: Sandwich ELISA
- Reacts with: Rat
Product nameAnti-Sclerostin antibody - BSA and Azide free (Detector)
See all Sclerostin primary antibodies
DescriptionRabbit monoclonal to Sclerostin - BSA and Azide free (Detector)
Tested applicationsSuitable for: Sandwich ELISAmore details
Species reactivityReacts with: Rat
ab267448 is a BSA and Azide Free antibody supplied in an unconjugated format and it is suitable for sandwich ELISAs to quantify Rat Sclerostin. The recommended pair for sandwich ELISA is:
Capture: ab267447, Rat Sclerostin (SOST) Capture Antibody (unconjugated)
Detector: ab267448, Rat Sclerostin (SOST) Detector Antibody (unconjugated)
The reference range value is 15.625 - 1000 pg/ml.
The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is a recombinant monoclonal antibody, which offers several advantages including:
-High batch-to-batch consistency and reproducibility
-Improved sensitivity and specificity
-Long-term security of supply
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C.
Concentration information loading...
sELISA pair antibody
Our Abpromise guarantee covers the use of ab267448 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration. Can be paired for Sandwich ELISA with PE / R-Phycoerythrin Conjugation Kit - Lightning-Link® (ab102918) and Biotinylation Kit / Biotin Conjugation Kit (Fast and Type A) - Lightning-Link® (ab201795).|
FunctionNegative regulator of bone growth.
Tissue specificityWidely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteeoblasts differentiated for 21 days.
Involvement in diseaseDefects in SOST are the cause of sclerosteosis (SOST) [MIM:269500]; also known as cortical hyperostosis with syndactyly. SOST is an autosomal recessive sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients.
Note=A 52 kb deletion downstream of SOST results in SOST transcription suppression and is a cause of van Buchem disease (VBCH) [MIM:239100]; also known as hyperostosis corticalis generalisata. VBCH is an autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated.
Sequence similaritiesBelongs to the sclerostin family.
Contains 1 CTCK (C-terminal cystine knot-like) domain.
- Information by UniProt
- BEER antibody
- CDD antibody
- Cortical hyperostosis with syndactyly antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab267448 has not yet been referenced specifically in any publications.